Grace Mantus
YOU?
Author Swipe
View article: Cross-neutralizing and potent human monoclonal antibodies against historical and emerging H5Nx influenza viruses
Cross-neutralizing and potent human monoclonal antibodies against historical and emerging H5Nx influenza viruses Open
View article: Longitudinal Surveillance of COVID-19 Antibodies in Pediatric Healthcare Workers
Longitudinal Surveillance of COVID-19 Antibodies in Pediatric Healthcare Workers Open
Background: Vaccines against COVID-19 target the spike protein. There is minimal information on longitudinal COVID-19 immune profiling in recovered versus naïve and vaccinated versus non-vaccinated healthcare workers (HCWs). Methods: This …
View article: Corrigendum to “Incidence of SARS-CoV-2 seropositivity in pediatric healthcare workers prior to widespread vaccination: A 5-month longitudinal cohort study” [Internation Journal of Infectious Diseases, volume 144 (2024) 107064]
Corrigendum to “Incidence of SARS-CoV-2 seropositivity in pediatric healthcare workers prior to widespread vaccination: A 5-month longitudinal cohort study” [Internation Journal of Infectious Diseases, volume 144 (2024) 107064] Open
View article: Analysis of Memory Antibody Responses in Individuals with Zika-Associated Guillain–Barré Syndrome
Analysis of Memory Antibody Responses in Individuals with Zika-Associated Guillain–Barré Syndrome Open
The Zika virus (ZIKV) was responsible for a major outbreak in 2015 in the Americas. Infections were associated with increased cases of microcephaly in infants and Guillain–Barré Syndrome (GBS) in adults. Our group previously demonstrated t…
View article: Incidence of SARS-CoV-2 seropositivity in pediatric healthcare workers prior to widespread vaccination: A 5-month longitudinal cohort study
Incidence of SARS-CoV-2 seropositivity in pediatric healthcare workers prior to widespread vaccination: A 5-month longitudinal cohort study Open
The incidence of seropositivity was 8.2%. Although seropositivity was higher among ED staff during the early stages of the pandemic, this difference declined over time, likely due to the universal adoption of personal protective equipment.
View article: Infants and young children generate more durable antibody responses to SARS-CoV-2 infection than adults
Infants and young children generate more durable antibody responses to SARS-CoV-2 infection than adults Open
View article: Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopes
Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopes Open
View article: Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody response
Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody response Open
View article: Infants and young children generate more durable antibody responses to SARS-CoV-2 infection than adults
Infants and young children generate more durable antibody responses to SARS-CoV-2 infection than adults Open
Since the emergence of SARS-CoV-2, research has shown that adult patients mount broad and durable immune responses to infection. However, response to infection remains poorly studied in infants/young children. In this study, we evaluated h…
View article: Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody response
Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody response Open
A detailed understanding of the molecular features of the neutralizing epitopes developed by viral escape mutants is important for predicting and developing vaccines or therapeutic antibodies against continuously emerging SARS-CoV-2 varian…
View article: Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody
Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody Open
In this study, by characterizing several human monoclonal antibodies (mAbs) isolated from single B cells of the COVID-19–recovered individuals in India who experienced ancestral Wuhan strain (WA.1) of SARS-CoV-2 during early stages of the …
View article: Loss of Pfizer (BNT162b2) Vaccine-Induced Antibody Responses against the SARS-CoV-2 Omicron Variant in Adolescents and Adults
Loss of Pfizer (BNT162b2) Vaccine-Induced Antibody Responses against the SARS-CoV-2 Omicron Variant in Adolescents and Adults Open
While plasma binding and neutralizing antibody responses have been reported for cohorts of infected and vaccinated adults, much less is known about the vaccine-induced antibody responses to variants including Omicron in children. This illu…
View article: Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant
Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant Open
PURPOSE To examine COVID-19 mRNA vaccine–induced binding and neutralizing antibody responses in patients with non–small-cell lung cancer (NSCLC) to SARS-CoV-2 614D (wild type [WT]) strain and variants of concern after the primary 2-dose an…
View article: Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody
Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody Open
The SARS-CoV-2 BA.1 and BA.2 (Omicron) variants contain more than 30 mutations within the spike protein and evade therapeutic monoclonal antibodies (mAbs). Here, we report a receptor-binding domain (RBD) targeting human antibody (002-S21F2…
View article: Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination
Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination Open
To determine the breadth and durability of humoral immunity to SARS-CoV-2 mRNA vaccination.
View article: mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant
mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant Open
View article: Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern
Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern Open
Purpose We investigated SARS-CoV-2 mRNA vaccine-induced binding and live-virus neutralizing antibody response in NSCLC patients to the SARS-CoV-2 wild type strain and the emerging Delta and Omicron variants. Methods 82 NSCLC patients and 5…
View article: Molecular Basis of SARS-CoV-2 Omicron Variant Evasion from Shared Neutralizing Antibody Response
Molecular Basis of SARS-CoV-2 Omicron Variant Evasion from Shared Neutralizing Antibody Response Open
View article: Loss of Pfizer (BNT162b2) Vaccine-Induced Antibody Responses Against the SARS-CoV-2 Omicron Variant in Adolescents and Adults
Loss of Pfizer (BNT162b2) Vaccine-Induced Antibody Responses Against the SARS-CoV-2 Omicron Variant in Adolescents and Adults Open
View article: mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant
mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant Open
The BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines generate potent neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the global emergence of SARS-CoV-2 variants with mutatio…
View article: Secretory phospholipase A2 in SARS-CoV-2 infection and multisystem inflammatory syndrome in children (MIS-C)
Secretory phospholipase A2 in SARS-CoV-2 infection and multisystem inflammatory syndrome in children (MIS-C) Open
Secretory phospholipase 2 (sPLA2) acts as a mediator between proximal and distal events of the inflammatory cascade. Its role in SARS-CoV-2 infection is unknown, but could contribute to COVID-19 inflammasome activation and cellular damage.…
View article: Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells
Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells Open
View article: Altered amino acid profile in patients with SARS-CoV-2 infection
Altered amino acid profile in patients with SARS-CoV-2 infection Open
Low plasma arginine bioavailability has been implicated in endothelial dysfunction and immune dysregulation. The role of arginine in COVID-19 is unknown, but could contribute to cellular damage if low. Our objective was to determine argini…
View article: Evaluation of Cellular and Serological Responses to Acute SARS-CoV-2 Infection Demonstrates the Functional Importance of the Receptor-Binding Domain
Evaluation of Cellular and Serological Responses to Acute SARS-CoV-2 Infection Demonstrates the Functional Importance of the Receptor-Binding Domain Open
The factors that control the development of an effective immune response to the recently emerged SARS-CoV-2 virus are poorly understood. In this study, we provide a cross-sectional analysis of the dynamics of B cell responses to SARS-CoV-2…
View article: Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells
Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells Open
SUMMARY Ending the COVID-19 pandemic will require long-lived immunity to SARS-CoV-2. Here, we evaluate 254 COVID-19 patients longitudinally up to eight months and find durable broad-based immune responses. SARS-CoV-2 spike binding and neut…
View article: Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant
Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant Open
View article: Prevalence of SARS-CoV-2 antibodies in pediatric healthcare workers
Prevalence of SARS-CoV-2 antibodies in pediatric healthcare workers Open
View article: Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India
Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India Open
View article: Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant
Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant Open
SUMMARY The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising concerns about the efficacy of infection- or vaccine-induced antibodies to neutralize these variants. We compared antibody binding and live virus n…
View article: Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS‐CoV‐2 Neutralizing Antibodies
Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS‐CoV‐2 Neutralizing Antibodies Open
SARS‐CoV‐2 is a recently emerged human coronavirus that has escalated to a pandemic. There are currently no approved vaccines for SARS‐CoV‐2, which causes severe respiratory illness or death. Defining the antibody response to SARS‐CoV‐2 wi…